PRODUCT – Page 7

High-Dose Wegovy Demonstrates Enhanced Weight Loss in Phase III Trial

8 months ago talkbio0Tagged Nordisk, Novo Nordisk, Obesity, Phase 3 Clinical Trials, semaglutide, Step (specific stage), Up, Wegovy

Wegovy, semaglutide, obesity treatment, weight loss, Novo Nordisk, Phase III trial, STEP UP trial

Samsung Biologics Embarks on New Phase of Growth with Bio Campus II and ADC Services

8 months ago talkbio0Tagged Antibody-Drug Conjugates, Bio Campus II, Biological Factors, Capacity, CDMO, Contract agreement, development aspects, digital transformation, expansion, Manufacturing Organization, Plants, Samsung, Services

Samsung Biologics, Bio Campus II, Plant 5, antibody-drug conjugate (ADC) services, capacity expansion, digital transformation, contract development and manufacturing organization (CDMO)

Key Takeaways from #JPM25: Strategic Partnerships and Acquisitions Dominate the JP Morgan Healthcare Conference

8 months ago talkbio0Tagged Acquisitions, Biopharma, Eli, Eli Lilly, Industry, J.P. Morgan Healthcare, JPM25, partnerships, Pharma, Scorpions, SmithKline Beecham, Zealand

JP Morgan Healthcare Conference, #JPM25, biopharma industry, acquisitions, partnerships, Eli Lilly, Zealand Pharma, GSK, Scorpion Therapeutics

Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial

8 months ago talkbio0Tagged GLP-1/GIP receptor dual agonist, Hengrui Pharmaceuticals, Kailera, Obesity, Phase 2 clinical trial, Weight Loss

HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics

AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment

8 months ago talkbio0Tagged AbbVie, bis(3-bis(4-chlorophenyl)methyl-4-dimethylaminophenyl)amine, CD3 Antigens, GPRC5D, GPRC5D gene, Multiple Myeloma, Simcere, T-Lymphocyte, Trispecific Antibody, Zaiming

AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3

Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol

8 months ago talkbio0Tagged ANGPTL4, Cardiovascular Diseases, cholesterol, MAR001, Marea Therapeutics, Monoclonal Antibodies, Phase 2 Clinical Trials, Remnant

Marea Therapeutics, MAR001, Remnant Cholesterol, Monoclonal Antibody, Cardiovascular Disease, ANGPTL4, Phase II Clinical Trial

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

8 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy